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ApoptosisIn our previous study, CARMA3 overexpression in lung cancer cells promoted cell proliferation and invasion;
however, themechanismunderlying the role of CARMA3 in cancer cell invasion remained unclear. In the present
study, knockdown of CARMA3 in A549 and H1299 cells suppressed cell invasion and migration, and downregu-
lated matrix metalloprotease 9 expression at the protein and mRNA levels, as shown by Western blotting and
real-time PCR. CARMA3 knockdown increased cell apoptosis, as shown by ﬂow cytometry, increased the
mRNA and protein expression levels of Bax and Caspase3, and downregulated Bcl-2 in A549 and H1299 cells.
Phosphorylated P38 levels increased and NF-кB activation decreased following knockdown of CARMA3.
SB203580, a P38 MAPK inhibitor, activated NF-кB, increased cell migration, and inhibited cell apoptosis after
knockdown of CARMA3 compared to knockdown of CARMA3 without SB203580. These ﬁndings indicate that
CARMA3may suppress the activation of the P38MAPK signaling pathway to regulate invasion,migration and ap-
optosis of lung cancer cells by activating NF-кB (P65) in the nucleus.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The human CARMA3 gene located on chromosome 22 q13. 1, also
known as caspase recruitment domain (CARD) and membrane-
associated guanylate kinase-like (GUK) domain gene, belongs to the
CARMA family. The proteins in the family are scaffold proteins, and
there are three members: CARMA1 (CARD11), CARMA2 (CARD14), and
CARMA3 (CARD10). These three proteins share similar structural motifs,
with an N-terminal CARD domain, followed by a coiled-coil domain, a
PDZ domain, an SH3 domain, and a C-terminal GUK domain. However,
they have different expression patterns, as CARMA1 is expressed in he-
matopoietic cells, CARMA2 is expressed in the placenta and several mu-
cosae, and CARMA3 is expressed in non-hematopoietic cells (Bertin et al.,
2001; Gaide et al., 2001;Wang et al., 2001;McAllister-Lucas et al., 2001).
Numerous studies have conﬁrmed that CARMA3 is overexpressed in
breast cancer, ovarian cancer, colorectal cancer and kidney cancer tissues
(Wu et al., 2013; Zhao et al., 2013; Miao et al., 2012; Mahanivong et al.,
2008), and that CARMA3 affects the proliferation, invasion andmigrationollege of Basic Medical Sciences,
irst Afﬁliated Hospital of China
nyang, China.
. This is an open access article underof tumor cells in associationwith the activation of nuclear factor-кB (NF-
кB) (Jiang et al., 2011). Recent studies showed that guanosine-binding
protein coupled receptor (GPCR), epidermal growth factor receptor
(EGFR) and protein kinase C (PKC) induced the activation of NF-кB by
CARMA3 (Jiang et al., 2011; Grabiner et al., 2007; McAllister-Lucas
et al., 2007), and several other studies indicated that GPCR and PKC re-
quire CARMA3 as well as its downstream signal components, MALT-1
and BCL10, to activate NF-кB (Jiang et al., 2011; McAllister-Lucas et al.,
2007;Wang et al., 2007; Klemmet al., 2007; Pan and Lin, 2013). Protease
activated receptor 1 signaling to NF-κB depends on initial PKC activation,
and a complex of proteins containing CARMA3, Bcl10 and MALT-1 links
PAR-1 activation to stimulation of the IκB kinase complex. IκB kinase in
turn phosphorylates IκB, leading to its degradation and the release of ac-
tive NF-κB in vascular endothelial cells (Delekta et al., 2010). Activation
of NF-кB confers resistance to apoptosis and enhances the proliferation
and migration ability of cancer cells (Hanahan and Weinberg, 2000).
Early research in our laboratory showed that CARMA3 is
overexpressed in non-small cell lung cancer tissues, and its expression
is associated with Tumor Node Metastasis (TNM) staging, lymph node
metastasis, and the expression of EGFR. CARMA3 promoted the prolifer-
ation, invasion, andmigration of lung cancer cells, andmay promote the
proliferation of lung cancer cells by upregulating cyclin D1 (Li et al.,
2012). However, the mechanism by which CARMA3 promotes thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 2
Dilution ratio of antibodies.
Name of the antibodies Manufacture Dilution ratio
Anti-CARMA3 Sigma 1:100
Anti-MMP9 Proteintech 1:500
Anti-MMP2 Proteintech 1:500
Anti-MMP7 Proteintech 1:500
Anti-BCL-2 Proteintech 1:500
Anti-Bax Proteintech 1:500
Anti-Caspase3 Proteintech 1:500
Anti-Caspase9 Proteintech 1:500
Anti-P65 Santa Cruz Biotechnology 1:100
Anti-P38 Cell Signaling 1:500
Anti-P-P38 Cell Signaling 1:500
Anti-P21 Cell Signaling 1:500
Anti-P73 Santa Cruz Biotechnology 1:100
Anti-N-Cadherin BD Biosciences 1:500
Anti-E-Cadherin BD Biosciences 1:500
Anti-AKT1/2 Santa Cruz Biotechnology 1:100
Anti-P-AKT Cell Signaling 1:500
Anti-GAPDH KANGCHEN 1:5000
Anti-LaminB Cell Signaling 1:200
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study focused on the mechanism underlying the promotion of cancer
cell invasion and migration, and the inhibition of lung cancer cell apo-
ptosis by CARMA3.
2. Materials and methods
2.1. Quantitative real-time PCR (SYBR Green Method)
For cDNA synthesis, a Prime Script ® RT reagent Kit with gDNA Eras-
er (TakaRa Dalian, China) was used. The reaction system consisted of
10 μl reaction mix (total RNA, 5 μl, 300 ng); the gene ampliﬁcation (G-
Storm, UK) complete reverse transcription experiment process was as
follows: 37 °C, 15 min; 85 °C, 5 s. Ampliﬁcation products were prepared
for real time PCR the next day, after−20 °C storage. Quantitative real-
time PCR was performed using SYBR Green PCR master mix (Applied
Biosystems) in a total volume of 20 ml on a 7900HT Fast Real-Time
PCR System (Applied Biosystems) as follows: 95 °C for 30 s, 40 cycles
of 95 °C for 5 s, 60 °C for 30 s. A dissociation stepwas performed to gen-
erate a melting curve to conﬁrm the speciﬁcity of the ampliﬁcation.
GAPDH was used as the reference gene. The relative levels of gene ex-
pression were expressed as ΔCt = Ct gene − Ct reference, and the
fold change of gene expression was calculated by the 2−ΔΔCt method.
The primer sequences are provided in Table 1. Experiments were per-
formed in triplicate.
2.2. Western blot analysis
Total proteins from primary tissues and cell lines were extracted in
lysis buffer (Thermo Fisher Scientiﬁc, Rockford, IL, USA) and quantiﬁed
using the Bradford method. Sixty micrograms of protein was separated
by SDS-PAGE (12%). After transferring, the polyvinylidene ﬂuoride
(PVDF) membranes (Millipore, Billerica, MA, USA) were incubated
overnight at 4 °C with the following antibodies (as shown in Table 2).
After incubation with peroxidase-coupled anti-mouse or rabbit or goat
IgG (Santa Cruz Biotechnology) at 37 °C for 2 h, bound proteinswere vi-
sualized using ECL (Thermo Fisher Scientiﬁc) and detected using a
BioImaging System (UVP Inc., Upland, CA, USA). The relative protein
levels were calculated based on GAPDH as the loading control.
2.3. Cell lines and small interfering RNA treatment
A549 and H1299 lung cancer cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and cultured in RPMI
1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serumTable 1
Real time PCR primer sequences.
Primer name Primer sequences
CARMA3 forward 5′-TCTTCCACCGTTGCCAATCT-3′
CARMA3 reverse 5′-TTCGCCTGCCAGGAACATC-3′
GAPDH forward 5′-AGAAGGCTGGGGCTCATTTG-3′
GAPDH reverse 5′-AGGGGCCATCCACAGTCTTC-3′
Bax forward 5′-TGTGGTCTATAATGCGTTTTCC-3′
Bax reverse 5′-GGCACTAATCAAGTCAAGGTCA-3′
BCL-2 forward 5′-ATTTCTCCTGGCTGTCTCTGAA-3′
BCL-2 reverse 5′-CAGGCATGTTGACTTCACTTGT-3′
Caspase3 forward 5′-AGTAGATGGTTTGAGCCTGAGC-3′
Caspase3 reverse 5′-GTATGGAGAAATGGGCTGTAGG-3′
MMP2 forward 5′-CCATTTTGATGACGATGAGCTA-3′
MMP2 reverse 5′-ACAAGAAGGGGAACTTGCAGTA-3′
MMP9 forward 5′-ACTTTGACAGCGACAAGAAGTG-3′
MMP9 reverse 5′-GGCACTGAGGAATGATCTAAGC-3′
TIMP-1 forward 5′-GCACATCACTACCTGCAGTC-3′
TIMP-1 reverse 5′-GAAACAAGCCCACGATTTAG-3′(Invitrogen), 100 IU/ml penicillin (Sigma, St. Louis, MO, USA), and
100 mg/ml streptomycin (Sigma). Cells were grown on sterile tissue
culture dishes and passaged every 2 days using 0.25% trypsin
(Invitrogen). SiRNA against CARMA3 and non-targeting siRNA were
purchased from RiBoBio (Guangzhou, China). For transfections, cells
were seeded in a six-well plate 24 h before the experiment. The cells
were transfected with siRNA (10 μl/well; RiBoBio) according to the
manufacturer's protocol. Following transfection, the mRNA and protein
levels were assessed 48 h later.2.4. Flow cytometry
After knocking down CARMA3 for 48 h, cells were harvested and
washed twice with cold PBS by gentle shaking. Resuspended cells
were added to binding buffer (1×) and cell density was adjusted to
200,000–500,000/ml. In the dark, 5 μl of Annexin V-FITC (50 mM TRIS,
100 mM NaCl, 1% BSA, 0.02% sodium azide, pH 7.4) was added to the
cell suspension in amix of 195 μl and incubated for 10min at room tem-
perature before adding 190 μl binding buffer (1×) and 10 μl propidium
iodide (PI). Ten thousand events per sample were acquired using a
FACS-scan ﬂow cytometer (Becton-Dickinson, San Jose, CA, USA) and
the percentage of apoptotic cells was analyzed using CellQuest analysis
software (Becton-Dickinson).2.5. Cell migration and invasion assays
Cell invasionwas assessed using a 24-well Transwell chamberwith a
pore size of 8 mm (Costar, Cambridge, MA, USA). The inserts were coat-
ed with 20mlMatrigel (1:3 dilution, BD Biosciences, San Jose, CA, USA).
Forty-eight hours after the transfection, cells were trypsinized and
40,000 cells in 100 μl of serum-free medium were transferred to the
upper Matrigel chamber and incubated for 24 h. The cell migration
assay was performed using a 24-well Transwell chamber with a pore
size of 8 mm (Costar). Forty-eight hours after the transfection, cells
were trypsinized and 30,000 cells in 100 μl of serum-free medium
were transferred to the upper Matrigel and incubated for 16 h. After in-
cubation, the non-invaded or non-migrated cells on the upper mem-
brane surface were removed with a cotton tip, and the cells that
passed through the ﬁlter were ﬁxed with 4% paraformaldehyde and
stained with hematoxylin. The number of invaded or migrated cells
was counted under microscope (OLYMPUS, Japan) in ﬁve randomly se-
lected high power ﬁelds. This experiment was performed in triplicate.
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SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) forWindowswas used
for all analyses. The Student's t-test was used to compare other data. P-
values were based on the two sided statistical analysis, and p b 0.05was
considered to indicate statistical signiﬁcance.
3. Results
3.1. CARMA3 knockdown reduces the invasion andmigration of lung cancer
cells
We used CARMA3 small interfering RNA (siRNA) to knock down
CARMA3 expression in the A549 and H1299 cell lines. After 48 h
of transfection, CARMA3mRNA and protein expression was signiﬁcant-
ly decreased in cells transfected with CARMA3 siRNA compared
with that in cells transfected with a random sequence siRNA (interfer-
ence efﬁciency was 78.2% in A549 cells and 81.2% in H1299 cells)
(Fig. 1A and B).
To further examine whether CARMA3 contributes to the migration
and invasion of non-small cell lung cancer cells, we performedMatrigel
migration and invasion assays. Our results showed that the migration
and invasion of CARMA3-knockdown A549 and H1299 cancer cells
were reduced compared with those in negative control cells (Fig. 1C
and D). These results demonstrate that CARMA3 is a positive regulator
of cell migration and invasion. We then examined the protein expres-
sion of anti-MMP9, anti-MMP2, anti-MMP7, anti-E-Cadherin and anti-
N-Cadherin in CARMA3-knockdown lung cancer cells. Western blot
analysis showed that MMP9 was downregulated at the mRNA and pro-
tein levels in CARMA3-knockdown cells (Fig. 1E–F).Fig. 1. CARMA3 knockdown in the cell lines A549 and H1299. (A) Real-time PCRwas performe
the protein expression of CARMA3. Knockdown of CARMA3 in H1299 and A549 cells inhibite
inhibited migration in both cell lines. (D) CARMA3 siRNA treatment inhibited invasion in both
graphs, and the standard deviation was calculated from the average number of cells in ten ﬁ
MMP9 and TIMP1 in A549 and H1299 cells, and GAPDH was used as the internal reference mR
MMP9, MMP7, E-Cadherin and N-Cadherin in A549 and H1299 cells, and GAPDH was used a
the CARMA3-knockdown group); * p b 0.05.To investigate the mechanism by which CARMA3 promoted the in-
vasion and migration of A549 and H1299 cells, we tested the effect of
CARMA3 knockdown on P38, P-P38, Akt, P-Akt and NF-кB (P65) levels.
As shown in Fig. 2A–F, Western blot analysis demonstrated that knock-
down of CARMA3 upregulated P-P38 and inactivated NF-кB (reduced
nucleoprotein levels of NF-кB indicated that activation of NF-кB was
suppressed), while no signiﬁcant differences were observed in the
other parameters.
3.2. Knockdown of CARMA3 following inhibition of P38 phosphorylation
increases NF-кB activation and lung cancer cell invasion
To determine whether the P38 MAPK pathway is involved in the
modulation of the NF-кB pathway by CARMA3, cells were treated with
SB203580 (a selective inhibitor of P38 that disrupts activation of down-
stream P38) for 2 h, followed by knockdown of CARMA3. SB203580 sig-
niﬁcantly restored CARMA3-knockdownmediatedNF-кB activation and
alterations in cell invasion (Fig. 3A and B). Treatment with SB203580
alone (for 2 h) had no signiﬁcant effect on NF-кB activation and alter-
ations in cell invasion.
3.3. CARMA3 inhibits apoptosis of lung cancer cells by activating NF-кB and
inhibiting P38 MAPK signaling
To determine whether CARMA3 affects the apoptosis of A549 and
H1299 cells, cells treated with CARMA3 siRNA were stained with
Annexin V and analyzed by ﬂow cytometry (Fig. 4A and B). The propor-
tion of pre-apoptotic cells in the CARMA3-knockdown groupwas signif-
icantly increased compared with that in the control group (all p b 0.01),
indicating that CARMA3 inhibited the apoptosis of A549 and H1299d to detect CARMA3mRNA expression. (B) Western blot analysis was performed to detect
d cell migration and invasion in a Boyden chamber assay. (C) CARMA3 siRNA treatment
cell lines. The bar graph indicates the mean and difference in cell numbers in the photo-
elds. (E and F) Real-time PCR was performed to detect the mRNA expression of MMP2,
NA. (G) Western blot analysis was performed to detect the protein expression of MMP2,
s the internal reference protein (NC represents the control group, SiCARMA3 represents
Fig. 2. Effect of CARMA3 knockdown in the cell lines A549 and H1299. (A)Western blot analysiswas performed to detect the protein expression of P38, P-P38, AKT and P-AKT in A549 and
H1299 cells, and GAPDHwas used as the internal reference protein. (B and C) Densitometric quantiﬁcation of theWestern blotting results. Data were normalized to GAPDH and each bar
represents themean± SD of three independent experiments. (D) After extraction of nucleoprotein and plasmosin,Western blot analysiswas performed to detect the expression of NF-кB
(P65), and Lamin B and GAPDHwere used as the internal reference proteins. (E and F) Densitometric quantiﬁcation of theWestern blotting results. Data were normalized to Lamin B and
GAPDH, and each bar represents the mean ± SD of three independent experiments. *p b 0.05 compared with negative control cells.
Fig. 3. A549 and H1299 cells were left untreated or treated with NC (10 μM) or SiCARMA3 (10 μM) for 48 h following exposure to SB203580 (a selective P38 inhibitor that disrupts acti-
vation of P38) for 2 h. (A, B)Western blot analysis of the protein expression of P-P38 andMMP9, as well as the nucleoprotein expression of NF-кB (P65), with GAPDH and Lamin B as the
internal reference proteins, respectively. The cell invasion assay was performed using a 24-well Transwell chamber with a pore size of 8mm. The inserts were coatedwith 20mlMatrigel
(1:3 dilution). Forty-eight hours after transfection, the cells were trypsinized and 40,000 cells in 100 μl of serum-free medium were transferred to the upper Matrigel chamber and incu-
bated for 24 h. The bar graph indicates the mean and difference in cell numbers in the photographs, and the standard deviation was calculated from the average number of cells in ten
ﬁelds. Each bar represents the mean ± SD of three independent experiments,*p b 0.05 (“−” represents DMSO as the control group and “+” represents the SB203580 group).
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Fig. 4. A549 (A) and H1299 (B) cells were transfected with CARMA3 siRNA for 48 h. After treatment, apoptosis was estimated using Annexin V staining as described in Materials and
methods. Each bar represents the mean ± SD of three independent experiments (**p b 0.01 compared with controls), (C and D). Real-time PCR was performed to detect the mRNA ex-
pression of Bcl-2, Caspase3 and Bax in A549 and H1299 cells (*p b 0.05). (E and F) Western blot analysis was performed to detect the protein expression of Bcl-2, Caspase3, Bax, P21 and
P73 in A549 and H1299 cells. GAPDH was used as the internal reference mRNA or protein (NC represents the control group and SiCARMA3 represents the CARMA3-knockdown group).
(F) Densitometric quantiﬁcation of theWestern blot experiments. Data were normalized to GAPDH, and each bar represents the mean± SD of three independent experiments. *p b 0.05,
compared with negative control cells.
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inhibited apoptosis in A549 and H1299 cells, Western blotting and
real-time PCR assays were performed. As shown in Fig. 4C–F, anti-
apoptotic Bcl-2 was downregulated and pro-apoptotic Bax and
Caspase3 were upregulated at the protein and mRNA levels in the
CARMA3-knockdown group compared with the control group (all p b
0.05), while there were no signiﬁcant differences in the other parame-
ters. These results indicated that the role of CARMA3 as an inhibitor of
apoptosis in NSCLC cells is predominantly mediated by Bcl-2 and Bax
as well as Caspase3, but not by p21 or P73.
Todeterminewhether the P38MAPKpathway is also involved in the
NF-кB pathway of CARMA3, the cells were treated with SB203580 for
2 h, followed by knockdown of CARMA3. SB203580 signiﬁcantly re-
stored CARMA3-knockdown mediated NF-кB activation and alterations
in cell apoptosis (Figs. 5A–F, 6A–D, and 7A–D). Treatment with
SB203580 alone for 2 h had no signiﬁcant effect on NF-кB activation
and alterations in cell apoptosis.4. Discussion
CARMA3 is a scaffold protein that promotes proliferation, migration,
and invasion and inhibits the apoptosis of tumor cells, and increased ex-
pression of CARMA3 is closely related to malignancy (Wu et al., 2013;
Zhao et al., 2013; Miao et al., 2012; Mahanivong et al., 2008). EGFR
and GPCR induce the formation of a complex composed of CARMA3
and its downstream signaling molecules, BCL10 and MALT-1 that acti-
vates IKK. IKK induces the degradation of I-кB, leading to the activation
of NF-кB and binding to DNA to induce the transcription of target genes
(Pan and Lin, 2013; Jiang et al., 2011; Sun and Lin, 2008; Sun and Yang,
2010; Ni et al., 2013). However, the mechanism by which CARMA3modulates signaling pathways that promote lung cancer cell invasion
and migration remains unclear.
In the present study, knockdown of CARMA3 inhibited themigration
and invasion of A549 and H1299 cells. To investigate the underlying
mechanism, we examined the effect of CARMA3-knockdown on the
levels ofMMP9,MMP2,MMP7, E-Cadherin, and N-Cadherin. Our results
showed that knockdown of CARMA3 downregulated MMP9 and sup-
pressed the activation of NF-кB. Tumor cell invasion and metastasis
are closely related and associated with the induction of proteases that
degrade the extracellularmatrix and basementmembrane.MMP9 is ac-
tivated by collagenase and the production of type IV collagenase, which
can destroy type IV and V collagen near the surface of tumors, which
then promotes tumor cell inﬁltration into the surrounding tissue, even-
tually leading to tumor invasion and metastasis (Werner et al., 2002;
Gao et al., 2014).
We suppressed the phosphorylation of P38 using appropriate con-
centrations of the inhibitor SB203580 followed by knockdown of
CARMA3, and observed an increase in the number of migratory cells
and the activation of NF-кB compared with the CARMA3-knockdown
group without inhibitor treatment. However, activation of NF-кB was
not restored in the control group without CARMA3 knockdown. Previ-
ous studies showed that NF-кB acts as a downstream effector of p38 in
the downregulation of RAGE by retinol, as NF-кB inhibition by SN50
and siRNA against p65 blocked the effect of retinol on RAGE, and p38 in-
hibitors reversed NF-кB activation in the human lung cancer cell line
A549 (De Bittencourt Pasquali et al., 2013). These ﬁndings show that
CARMA3 may activate NF-кB by suppressing the P38 MAPK pathway,
as it did not fully restore the activation of NF-кB induced by knockdown
of CARMA3 in the presence of an inhibitor of the P38 MAPK pathway.
NF-кB signals play an important role in the development of cancer
(Basseres and Baldwin, 2006; Karin, 2006; Mantovani et al., 2008;
Fig. 5. A549 and H1299 cells were untreated or treatedwith NC (10 μM) or SiCARMA3 (10 μM) for 48 h following exposure to SB203580 for 2 h. After treatment, apoptosis was estimated
using Annexin V staining as described in Materials and methods in A549 (A and B) and H1299 (C and D) cells. Each bar represents the mean ± SD of three independent experiments,
*p b 0.05, compared with control cells.
Fig. 6. A549 and H1299 cells were untreated or treated with NC (10 μM) or SiCARMA3 (10 μM) for 48 h following exposure to SB203580 for 2 h. After treatment, Western blotting was
performed to detect the protein expression of Bcl-2 and Bax in A549 (A) and H1299 (D) cells, and GAPDHwas used as the internal reference protein. The results or densitometric quan-
tiﬁcation of theWestern blot experiments on A549 (B and C) cells and H1299 (E and F) cells are shown. Data were normalized against GAPDH, and each bar represents themean± SD of
three independent experiments. *p b 0.05, compared with negative control cells.
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Fig. 7. A549 and H1299 cells were untreated or treated with NC (10 μM) or SiCARMA3 (10 μM) for 48 h following exposure to SB203580 for 2 h. Western blot analysis was performed to
detect nucleoprotein and plasmosin expression of NF-кB (P65) in A549 (A) and H1299 (C) cells, and Lamin B and GAPDH were used as the internal reference proteins, respectively. The
results of densitometric quantiﬁcation ofWestern blot experiments onA549 andH1299 (B andD) cells are shown.Datawerenormalized to LaminB andGAPDH, respectively, and eachbar
represents the mean ± SD of three independent experiments. *p b 0.05, compared with negative control cells.
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ing pathways, activate the NF-кB transcription factor, and then induce
the expression of MMP9 in vascular smooth muscle cells (Zhang et al.,
2013). These ﬁndings suggest that CARMA3 regulates the activation of
NF-кB by suppressing the P38 MAPK pathway, and consequently pro-
motes lung cancer invasion and migration via the regulation of MMP9
expression.
CARMA3-knockdown resulted in an increase in the number of apo-
ptotic cells. We examined the possible mechanism by which CARMA3
inhibits the apoptosis of A549 and H1299 cells and showed that the
mRNA and protein expression levels of Bax increased, whereas Bcl2
levels decreased. Bcl-2 and Bax are regulatory factors of cell apoptosis,
and can modulate the integrity of the mitochondrial outer membrane
(Wei et al., 2001; Ewings et al., 2007; Cory and Adams, 2002). Some
members of the Bcl-2 family are located in the mitochondrial mem-
brane and can alter the permeability of the mitochondrial membrane,Fig. 8. Summary graphtriggering the activation of caspase leading to apoptotic cell death
(Strasser, 2005; Adams and Cory, 1998; Antonsson and Martinou,
2000). Members of the Bax family aremainly located in the outer mem-
brane surface of mitochondria or in the cytoplasm; their interaction
with the mitochondrial membrane leads to changes in permeability,
loss of the transmembrane potential, and release of cytochrome C and
other proteins (Eskes et al., 2000). These ﬁndings suggest that
CARMA3 may regulate lung cancer cell apoptosis by regulating the ex-
pression of Bcl-2 and Bax. We showed that CARMA3 could regulate
NF-кB activation by the P38 MAPK signaling pathway. We used the in-
hibitor SB203580 to suppress the phosphorylation of P38 and then
knocked down CARMA3. Our results showed a reduction in the number
of apoptotic cells, an increase in NF-кB activation, and the downregula-
tion of Bcl-2 and upregulation of Bax at the mRNA and protein levels
compared with the CARMA3-knockdown group without inhibitor.
However, activation of NF-кB was not restored in the group withoutof the manuscript.
360 Z.X. Xia et al. / Experimental and Molecular Pathology 100 (2016) 353–360knockdown of CARMA3. These ﬁndings require further investigation.
(E)-2,4-bis(p-hydroxyphenyl)-2-butenal induces apoptosis in NSCLC
cells (NCI-H460 and A549 cells) through the p38 MAPK-mediated sup-
pression of NF-κB and activation of DR5, which then activates the
caspase-3 and caspase-9 pathways (Kollipara et al., 2013). These results
suggest that CARMA3 may activate NF-кB by inhibiting the P38 MAPK
pathway, modulating the expression of Bax and Bcl-2 and regulating
lung cancer cell apoptosis.
Lung cancer is a commonmalignant tumor in humans, and there are
many potentially useful lung cancer biomarkers, such as CEA and CA-
125 (Miramar et al., 2001; Barlesi et al., 2004; Ando et al., 2003). In
the present study, we showed that CARMA3 promoted the invasion
and migration of lung cancer cells and inhibited cell apoptosis by sup-
pressing the phosphorylation of P38 and activation of NF-кB, leading
to the modulation of MMP9, Bax, and Bcl-2 expression. CARMA3 can
promote cell proliferation, migration and invasion in tumor cells, and
inhibit apoptosis. These ﬁndings provide a theoretical basis for research
into the signaling pathways related to CARMA3, which could be of value
for the early diagnosis of lung cancer and the design of targeted thera-
pies (Fig. 8).
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